2022
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, Spring LM, Faggen M, Constantine M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, Krop IE, Tung NM, Tayob N, King TA, Mittendorf EA, Winer EP. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. Npj Breast Cancer 2022, 8: 63. PMID: 35538105, PMCID: PMC9091255, DOI: 10.1038/s41523-022-00429-7.Peer-Reviewed Original ResearchPathologic complete responseProspective trialBreast cancerSingle-arm prospective trialHER2-positive breast cancerHuman epidermal growth factor receptorAdjuvant treatment plansDose of THPEarly-stage HER2Incomplete clinical responsePrimary feasibility endpointTrastuzumab/pertuzumabMajority of patientsOngoing prospective trialsStage II tumorsLong-term efficacyBreast cancer recurrenceEpidermal growth factor receptorAdjuvant chemotherapyFeasibility endpointsGrowth factor receptorNeoadjuvant regimenAdjuvant therapyDoublet therapyPrimary endpoint
2016
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study
Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso K, Metzger-Filho O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. The Breast 2016, 30: 136-140. PMID: 27721193, DOI: 10.1016/j.breast.2016.09.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantCyclophosphamideDoxorubicinFemaleGranulocyte Colony-Stimulating FactorHumansMiddle AgedNeutropeniaPaclitaxelPractice Patterns, Physicians'Retrospective StudiesYoung AdultConceptsGranulocyte-colony stimulating factorDose-dense paclitaxelTreatment delayGroup 1High baseline absolute neutrophil countBaseline absolute neutrophil countSingle-institution retrospective studyDana-Farber Cancer InstituteStimulating factorRoutine G-CSFPercent of patientsRetrospective cohort studyAbsolute neutrophil countMajority of patientsAdverse eventsCohort studyNeutrophil countTreatment cessationProspective studyRetrospective studyT therapyBreast cancerGroup 2PatientsCancer Institute
2009
Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148).
Berry D, Berry D, Thor A, Jewell S, Broadwater G, Edgerton S, Hayes D, Hudis C, Winer E, Nielsen T, Ellis M. Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148). Cancer Research 2009, 69: 606-606. DOI: 10.1158/0008-5472.sabcs-09-606.Peer-Reviewed Original ResearchAdjuvant doxorubicin/cyclophosphamideNode-positive breast cancerWhole section analysisTissue microarrayHazard ratioER statusBreast cancerAdjuvant phase III trialsDouble-negative tumorsDoxorubicin/cyclophosphamideNon-responding patientsPhase III trialsMajority of patientsMultivariate Cox modelConfidence intervalsTumor tissue microarraysSet of patientsTMA cohortHormonal therapyIII trialsSurvival benefitCentral pathologyPathology blocksKaplan-MeierClinical assessment
1999
Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support
Winer E, Lindley C, Hardee M, Sawyer W, Brunatti C, Borstelmann N, Peters W. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psycho-Oncology 1999, 8: 167-176. PMID: 10335560, DOI: 10.1002/(sici)1099-1611(199903/04)8:2<167::aid-pon354>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsFunctional Living Index-CancerHigh-dose chemotherapyQuality of lifeAutologous bone marrow supportBone marrow supportSymptom Distress ScaleDose chemotherapyBreast cancerMarrow supportSexual functioningMajority of patientsBreast cancer patientsLong-term outcomesTreatment of patientsMore yearsFLIC scoresTransplant supportIndex cancerRecurrent diseaseAssessment of qualityMedian timeCancer patientsSexual functionClinical trialsSevere symptoms
1998
Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.
Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. Journal Of Clinical Oncology 1998, 16: 1380-7. PMID: 9552041, DOI: 10.1200/jco.1998.16.4.1380.Peer-Reviewed Original ResearchConceptsFunctional Living Index-CancerQuality of lifeEarly-stage breast cancerSystemic adjuvant therapyMonths of chemotherapySymptom Distress ScaleAdjuvant therapySexual functionBreast cancerSevere symptomsMedical Outcomes Study Short Form-36Self-rated QOLThird of patientsMajority of patientsShort Form-36Breast cancer patientsPatient's physical symptomsSite of surgeryModest potential benefitAdjuvant cytotoxicAdjuvant treatmentHormonal therapyIndex cancerForm-36Local numbness